Secondly, mutation status holds prognostic value, with certain KRAS mutants correlating with adverse outcomes; for instance, colorectal cancer patients harboring KRAS mutations typically exhibit a poorer prognosis than their wild-type counterparts [64,65,66]. The gene discussed is KRAS; the disease is colorectal cancer.